New insights on CA 19-9 dynamics can enhance treatment strategies for pancreatic cancer patients undergoing surgery. In a study with 283 patients, median overall survival was 56.3 months, and recurrence-free survival was 26.0 months. Patients categorized as type 1 (preoperative normalization) or type 2 (post-surgery normalization) had a significantly better prognosis (overall survival of 61.1 […]
Category: HPB & Spleen
Tailored Chemotherapy for Gallbladder Cancer: A Better Approach
A prognostic model for gallbladder cancer can refine adjuvant chemotherapy decisions and improve patient outcomes. In a study of 2,252 patients, age, tumor grade, N stage, tumor size, and sex predicted overall survival more accurately than the TNM system. The 5-year overall survival rate was only 27.3%. High-risk patients saw improved survival with adjuvant chemotherapy, […]
Trisectionectomies Enhance Outcomes in Bismuth Type II-III Cholangiocarcinoma
Trisectionectomies significantly improve survival for patients with localized Bismuth-Corlette type II-III perihilar cholangiocarcinoma. Overall survival improved to 52.4 months with trisectionectomy vs. 31 months for extended hemihepatectomy (p < 0.001). R0 resection rates were higher with trisectionectomies (83.9% vs. 75.8%, p = 0.037). Consider trisectionectomies for appropriate patients to enhance oncological outcomes without increasing significant […]
Liver Resection for Colorectal Metastases Sets New Outcomes Benchmark
Liver resection remains a gold standard for colorectal liver metastases, providing critical data for patient selection and surgical outcomes. 90-day mortality rate is under 5% across most groups, signaling low operative risk. One-year overall survival exceeds 85% for most subgroups, but drops to 78% for patients with 10 or more metastases. Timely assessment of these […]
New model predicts early recurrence risk in pancreatic tumors
Surgeons can now identify non-functioning pancreatic neuroendocrine tumors at high risk for early recurrence preoperatively. Early recurrence occurred in 11% of patients, with a median disease-free survival of 16 months. Neoplastic venous thrombosis predicted a 71% chance of early recurrence; without it, patients with a KI-67 index ≥5% and tumor size ≥3 cm had a […]
New model predicts poor outcomes in liver surgery for HCC
Surgeons now have a validated model to identify patients at high risk for early non-curative recurrence after liver resection for hepatocellular carcinoma (HCC), crucial for tailoring postoperative care. Early non-curative recurrence significantly increases overall survival risk (hazard ratio 5.39). Median survival drops from 178.6 months to just 34.7 months in early recurrence cases (p < […]
ICG Navigation Outperforms Conventional Technique for Hepatic Hemangioma
Using indocyanine green (ICG) fluorescence navigation in laparoscopic hepatectomy leads to better outcomes for hepatic hemangioma patients. Median blood loss: 100 ml (ICG) vs 200 ml (conventional), p < 0.001. Hospital stays shortened: 5.9 days (ICG) vs 7.1 days (conventional), p < 0.001. For patients with an Iwate score above 9, ICG significantly reduced operative […]
Surgical Resection Boosts Survival in HCC After Triple Therapy
Surgical resection significantly improves survival for hepatocellular carcinoma patients who reach complete response following triple therapy. One-, two-, and three-year survival rates post-surgery were 96.0%, 90.8%, and 90.8%, compared to 91.3%, 85.8%, and 73.1% for nonsurgical management. Patients who underwent surgery saw 70.9% achieve pathological complete response; however, the overall complication rate was 24.2%. Surgical […]
Predictive nomogram reduces futile surgery in gallbladder cancer
Surgeons can now better identify patients who may not benefit from surgery for gallbladder cancer. 11.1% of patients experienced ‘futile surgery’ with a median survival of only 8.9 months. Those who received successful surgical intervention had a median survival of 88.7 months (p < 0.001). Incorporating this nomogram into preoperative decision-making may significantly reduce unnecessary […]
Albumin-Bilirubin Score Predicts Outcomes in HCC After TACE
A new meta-analysis shows the Albumin-Bilirubin (ALBI) score is crucial for predicting survival and liver function in hepatocellular carcinoma patients treated with transhepatic arterial chemoembolization (TACE). Higher ALBI grades significantly correlate with shorter overall survival: 2nd vs. 1st grade (1.52 times higher risk); 3rd vs. 1st (2.67 times); and 3rd vs. 2nd (1.94 times). The […]
